ATE496916T1 - Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor - Google Patents

Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor

Info

Publication number
ATE496916T1
ATE496916T1 AT07824574T AT07824574T ATE496916T1 AT E496916 T1 ATE496916 T1 AT E496916T1 AT 07824574 T AT07824574 T AT 07824574T AT 07824574 T AT07824574 T AT 07824574T AT E496916 T1 ATE496916 T1 AT E496916T1
Authority
AT
Austria
Prior art keywords
arylcycloheptancarboxic
quiniclidine
hetero
antagonists
derivatives
Prior art date
Application number
AT07824574T
Other languages
English (en)
Inventor
Rhonan Ford
Andrew Mather
Antonio Mete
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Application granted granted Critical
Publication of ATE496916T1 publication Critical patent/ATE496916T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/08—Antibacterial agents for leprosy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Reproductive Health (AREA)
  • Emergency Medicine (AREA)
  • Molecular Biology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
AT07824574T 2006-11-14 2007-11-13 Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor ATE496916T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US86566706P 2006-11-14 2006-11-14
US86938406P 2006-12-11 2006-12-11
PCT/GB2007/004350 WO2008059245A1 (en) 2006-11-14 2007-11-13 Quiniclidine derivatives of (hetero) arylcycloheptanecarboxylic acid as muscarinic receptor antagonists

Publications (1)

Publication Number Publication Date
ATE496916T1 true ATE496916T1 (de) 2011-02-15

Family

ID=39048793

Family Applications (1)

Application Number Title Priority Date Filing Date
AT07824574T ATE496916T1 (de) 2006-11-14 2007-11-13 Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor

Country Status (30)

Country Link
US (2) US8207193B2 (de)
EP (2) EP2094694B1 (de)
JP (1) JP4904402B2 (de)
KR (1) KR20090078828A (de)
AR (1) AR063804A1 (de)
AT (1) ATE496916T1 (de)
AU (1) AU2007321019B2 (de)
BR (1) BRPI0718750A2 (de)
CA (1) CA2669326A1 (de)
CL (1) CL2007003260A1 (de)
CO (1) CO6160312A2 (de)
CY (1) CY1111351T1 (de)
DE (1) DE602007012300D1 (de)
DK (1) DK2094694T3 (de)
EC (1) ECSP099338A (de)
HK (1) HK1134091A1 (de)
HR (1) HRP20110178T1 (de)
IL (1) IL198314A (de)
MX (1) MX2009004780A (de)
MY (1) MY148392A (de)
NO (1) NO20092224L (de)
NZ (1) NZ576679A (de)
PE (1) PE20081164A1 (de)
PL (1) PL2094694T3 (de)
PT (1) PT2094694E (de)
RS (1) RS51650B (de)
RU (1) RU2456286C2 (de)
SA (1) SA07280616B1 (de)
TW (1) TW200825084A (de)
WO (1) WO2008059245A1 (de)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2438915A1 (de) * 2006-07-21 2012-04-11 Mars Incorporated Verbesserung von Arginase-Spiegeln und -Aktivität
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2009139708A1 (en) * 2008-05-13 2009-11-19 Astrazeneca Ab PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST
GB0808708D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
GB0808709D0 (en) * 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
NZ589091A (en) * 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0811099D0 (en) * 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
KR20110022611A (ko) * 2008-06-20 2011-03-07 아스트라제네카 아베 베타２－아드레날린수용체 활성의 조절을 위한, ４－히드록시－２－옥소－２,３－디히드로－１,３－벤조티아졸－７－일 화합물을 포함하는 제약 조성물
WO2010008341A1 (en) * 2008-07-16 2010-01-21 Astrazeneca Ab A combination of (a) glucocorticoid receptor modulator and (b) a muscarinic antagonist
GB0814729D0 (en) * 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
EP2206712A1 (de) * 2008-12-23 2010-07-14 CHIESI FARMACEUTICI S.p.A. Alkaloidaminoester-Derivate und medizinische Zusammensetzung davon
TW201036957A (en) 2009-02-20 2010-10-16 Astrazeneca Ab Novel salt 628
RU2636614C2 (ru) * 2009-05-19 2017-11-24 Вивия Байотек С.Л. Способы персонализированного медицинского тестирования ex vivo на гематологические новообразования
CN102947298B (zh) * 2010-06-22 2016-03-02 奇斯药制品公司 生物碱氨基酯衍生物及其药物组合物
JP2011195593A (ja) * 2011-06-30 2011-10-06 Astrazeneca Ab ムスカリンｍ３受容体アンタゴニストとしてのキヌクリジン誘導体
KR20150013206A (ko) 2012-04-30 2015-02-04 바이오테라, 인크. β-글루칸 면역요법을 위한 조성물 및 방법
TW201517906A (zh) 2013-07-25 2015-05-16 Almirall Sa 含有ｍａｂａ化合物和皮質類固醇之組合
TW201617343A (zh) * 2014-09-26 2016-05-16 阿爾米雷爾有限公司 具有β２腎上腺素促效劑及Ｍ３蕈毒拮抗劑活性之新穎雙環衍生物

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL62140C (de) * 1942-12-16
DE2104179C3 (de) 1971-01-29 1980-10-02 Knoll Ag, 6700 Ludwigshafen exo-2-Phenyl-bicyclo- [2,2,1] -heptan-2- (N-methylpiperidol-4)-carbonsäureester und dessen Salze, Verfahren zu deren Herstellung sowie diese enthaltende Arzneimittel
FR2155927A1 (en) 1971-10-15 1973-05-25 Synthelabo 1-phenylcyclo hexane carboxylic acid esters - with antispasmodic and anticholinergic activity
FR2168881A1 (en) 1972-01-25 1973-09-07 Synthelabo Tropanol 1-phenylcycloalkane carboxylic ester salts - spasmolytics and cholinergics
FR2208649A1 (en) 1972-12-01 1974-06-28 Synthelabo 1-(2-Thienyl)cycloalkane carboxylic ester salts - with spasmolytic and anticholinergic activity
GB8334494D0 (en) 1983-12-24 1984-02-01 Tanabe Seiyaku Co Carbostyril derivatives
IL77458A (en) 1985-01-14 1990-07-26 Eisai Co Ltd Cephem derivatives,their production and antibacterial compositions containing them and certain novel intermediates therefor
GR1001529B (el) 1990-09-07 1994-03-31 Elmuquimica Farm Sl Μέ?οδος για την λήψη νέων 21-εστέρων της 16-17-ακετάλης της πρ να-1,4-διενο-3,20-διόνης.
SE9003057D0 (sv) 1990-09-26 1990-09-26 Astra Ab New process
AU1578692A (en) 1991-03-07 1992-10-06 G.D. Searle & Co. New meso-azacyclic aromatic acid amides and esters as novel serotonergic agents
NO2005012I1 (no) * 1994-12-28 2005-06-06 Debio Rech Pharma Sa Triptorelin og farmasoytisk akseptable salter derav
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
BR9707495A (pt) 1996-02-13 1999-07-27 Zeneca Ltd Derivado de quinazolina processo para a preparação do mesmo composição farmacêutica e processo para a produç o de um efeito antiangiogênico e/ou de redução de permeabilidade vascular em um animal de sangue quente
KR100489174B1 (ko) 1996-03-05 2005-09-30 제네카-파마 소시에떼아노님 4-아닐리노퀴나졸린유도체
KR20000029703A (ko) 1996-07-29 2000-05-25 존 헤덴스트룀 아릴시클로알칸카르복실산에스테르,그것의용도,제약학적조성물및제조방법
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
US6613795B2 (en) 1996-11-11 2003-09-02 Christian Noe Enantiomerically pure basic arylcycloalkylhydroxycarboxylic esters, processes for their preparation and their use in medicaments
DK0937041T3 (da) 1996-11-11 2003-08-11 Christian R Noe Anvendelse af et farmaceutisk egnet salt af (3R,2'R)-3-[(cyclopentil-hydroxyphenylacetyl)oxyl]-1,1-dimethyl-pyrrolidinium til fremstilling af et lægemiddel
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
ES2165768B1 (es) 1999-07-14 2003-04-01 Almirall Prodesfarma Sa Nuevos derivados de quinuclidina y composiciones farmaceuticas que los contienen.
IL152682A0 (en) 2000-05-31 2003-06-24 Astrazeneca Ab Indole derivatives with vascular damaging activity
GB0015876D0 (en) 2000-06-28 2000-08-23 Novartis Ag Organic compounds
MXPA02012905A (es) 2000-07-07 2004-07-30 Angiogene Pharm Ltd Derivados de colquinol como agentes de dano vascular..
HUP0301742A3 (en) 2000-07-07 2005-08-29 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors, process for producing them, pharmaceutical compositions containing them and their use
MXPA03005583A (es) * 2000-12-22 2004-05-05 Almirall Prodesfarma Ag Derivados de carbamato de quinuclidina y su uso como antagonistas m3.
UA75626C2 (en) 2000-12-28 2006-05-15 Almirall Prodesfarma Ag Quinuclidine derivatives and medicinal compositions containing the same
DE60224172T2 (de) 2001-03-22 2008-12-04 Glaxo Group Ltd., Greenford Formanilid-derivative als beta2-adrenorezeptor-agonisten
EP1383730A2 (de) * 2001-04-03 2004-01-28 Aryx Therapeutics Anticholinerge verbindungen und anwendungsverfahren
JP4446661B2 (ja) 2001-04-30 2010-04-07 グラクソ グループ リミテッド 抗炎症性の、１７α位に環状エステル基を有するアンドロスタンの１７β−カルボチオ酸エステル誘導体
US20030229058A1 (en) 2001-11-13 2003-12-11 Moran Edmund J. Aryl aniline beta2 adrenergic receptor agonists
TWI249515B (en) 2001-11-13 2006-02-21 Theravance Inc Aryl aniline beta2 adrenergic receptor agonists
DE10216333A1 (de) 2002-04-13 2003-10-30 Boehringer Ingelheim Pharma Neue Carbonsäureester mit anticholonerger Wirksamkeit, Verfahren zu deren Herstellung sowie deren Verwendung als Arzneimittel
ES2206021B1 (es) 2002-04-16 2005-08-01 Almirall Prodesfarma, S.A. Nuevos derivados de pirrolidinio.
PL376396A1 (en) 2002-10-11 2005-12-27 Pfizer Inc. Indole derivatives as beta-2 agonists
US7056916B2 (en) 2002-11-15 2006-06-06 Boehringer Ingelheim Pharma Gmbh & Co. Kg Medicaments for the treatment of chronic obstructive pulmonary disease
AR044134A1 (es) * 2003-05-02 2005-08-24 Novartis Ag Derivados de quinuclidina, metodo de preparacion y composiciones farmaceuticas.
AR044851A1 (es) 2003-06-24 2005-10-05 Novartis Ag Compuestos heterociclicos, antagonistas del receptor m3 muscarinico
CN100450488C (zh) 2003-11-03 2009-01-14 诺顿·希尔思凯尔有限公司 用于干粉吸入剂的软类固醇组合物
JPWO2006025324A1 (ja) 2004-08-30 2008-05-08 小野薬品工業株式会社 トロパン化合物およびそれらを有効成分として含有する医薬組成物
WO2006035303A1 (en) 2004-09-29 2006-04-06 Ranbaxy Laboratories Limited Muscarinic receptor antagonists
BRPI0517263A (pt) 2004-10-29 2008-10-07 Astrazeneca Ab novos derivados de sulfonamida como moduladores do receptor de glicocorticóide para o tratamento de doenças inflamatórias
GB0424284D0 (en) * 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0428416D0 (en) 2004-12-24 2005-02-02 Novartis Ag Organic compounds
TW200722418A (en) 2005-04-20 2007-06-16 Astrazeneca Ab Novel compounds
MX2008001067A (es) 2005-08-01 2008-03-19 Astrazeneca Ab Derivados de piperidina novedosos como moduladores de receptor de quimioquina utiles para el tratamiento de enfermedades respiratorias.
TW200738635A (en) 2005-08-02 2007-10-16 Astrazeneca Ab New salt
GB0516313D0 (en) 2005-08-08 2005-09-14 Argenta Discovery Ltd Azole derivatives and their uses
US7994211B2 (en) 2005-08-08 2011-08-09 Argenta Discovery Limited Bicyclo[2.2.1]hept-7-ylamine derivatives and their uses
TW200738658A (en) 2005-08-09 2007-10-16 Astrazeneca Ab Novel compounds
TW200738659A (en) 2005-08-29 2007-10-16 Astrazeneca Ab Novel compounds
JP2009519310A (ja) 2005-12-16 2009-05-14 アージェンタ ディスカバリー リミテッド 環状アミン誘導体およびそれらの使用
JP2009534463A (ja) 2006-04-24 2009-09-24 アストラゼネカ・アクチエボラーグ 例えば慢性気管支閉塞、喘息および過活動膀胱の処置に有用な、ムスカリンｍ３受容体アンタゴニスト活性を有する環状アミノアルコールの新規アルキルエステル
WO2008010765A1 (en) 2006-07-19 2008-01-24 Astrazeneca Ab Novel tricyclic spiropiperidine compounds, their synthesis and their uses as modulators of chemokine receptor activity
WO2008017827A2 (en) 2006-08-08 2008-02-14 Argenta Discovery Limited Azole and thiazole derivatives and their uses
GB0702384D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Chemical compounds
WO2008023157A1 (en) 2006-08-21 2008-02-28 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as m3-receptor modulators
EP1894568A1 (de) 2006-08-31 2008-03-05 Novartis AG Pharmazeutische Zusammensetzungen zur Behandlung von entzündlichen oder obstruktiven Atemwegserkrankungen
TW200825084A (en) 2006-11-14 2008-06-16 Astrazeneca Ab New compounds 521
WO2008059239A1 (en) 2006-11-14 2008-05-22 Astrazeneca Ab Novel compounds 514
WO2008075006A1 (en) 2006-12-19 2008-06-26 Astrazeneca Ab Piperldinum compounds for treatment of obstructive pulmonary diseases ( copd)
EP2121137B1 (de) 2006-12-19 2012-04-25 AstraZeneca AB Chinuclidinol-derivate als muscarinrezeptor-antagonisten
TW200833670A (en) 2006-12-20 2008-08-16 Astrazeneca Ab Novel compounds 569
WO2008096094A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Bicyclor[2.2.1]hept-7-ylamine derivatives as muscarinic m3 receptor modulators
WO2008096093A1 (en) 2007-02-06 2008-08-14 Argenta Discovery Ltd. Oxazole and thiazole derivatives and their uses
WO2008096129A1 (en) 2007-02-07 2008-08-14 Argenta Discovery Ltd Nitrogen containing hetrocyclic compounds useful as bifunctional modulators of m3 receptors and beta- 2 receptors
GB0702382D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New salt
GB0702414D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd Oxazole and thiazole derivatives and their uses 2
GB0702413D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New chemical compounds
GB0702416D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
GB0702385D0 (en) 2007-02-07 2007-03-21 Argenta Discovery Ltd New combination
RU2459810C2 (ru) 2007-02-07 2012-08-27 Арджента Дискавери Лтд Нападизилатная соль антагониста мускаринового м3-рецептора
GB0702457D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination 666
GB0702456D0 (en) 2007-02-08 2007-03-21 Astrazeneca Ab New combination
CL2008000474A1 (es) 2007-02-15 2008-08-22 Argenta Discovery Ltd Compuestos derivados de azonia-biciclo-[2.2.2]octano, moduladores del receptor m3; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como epoc, asma, sindrome del intestino irritable, entre otras.
GB0704000D0 (en) 2007-03-01 2007-04-11 Astrazeneca Ab Salts 670
WO2008149110A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Limited Bicyclor [2.2.1] hept-7-ylamine derivatives and their use in the treatment of diseases and conditions in which m3 muscarinic receptor activity and beta-adrenergic activity are implicated
WO2008149053A1 (en) 2007-06-08 2008-12-11 Argenta Discovery Ltd. Bicycl0 [2. 2. 1] he pt- 2-ylamine derivates and their use
WO2009098453A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab Azonia bicycloalkanes as m3 muscarinic acetylcholin receptor antagonists
WO2009098455A1 (en) 2008-02-06 2009-08-13 Astrazeneca Ab 2- (9h-xanthen-9-yl) -oxazol derivatives as m3 muscarinic receptor antagonists for the treatment of asthma and chronic obstructive lung disease
NZ586872A (en) 2008-02-06 2012-03-30 Astrazeneca Ab Spirocyclic amide compounds
GB0808708D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New compounds 274
NZ589091A (en) 2008-05-13 2011-07-29 Astrazeneca Ab Quinuclidine derivatives as muscarinic m3 receptor antagonists
GB0808707D0 (en) 2008-05-13 2008-06-18 Argenta Discovery Ltd New compounds 275
WO2009139708A1 (en) 2008-05-13 2009-11-19 Astrazeneca Ab PHARMACEUTICAL PRODUCT COMPRISING A MUSCARINIC RECEPTOR ANTAGONIST AND A β2-ADRENOCEPTOR AGONIST
GB0808709D0 (en) 2008-05-13 2008-06-18 Astrazeneca Ab New combination 295
GB0811099D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination 376
GB0811100D0 (en) 2008-06-17 2008-07-23 Astrazeneca Ab New combination
WO2009153536A1 (en) 2008-06-17 2009-12-23 Argenta Discovery Limited 1-aza-bicyclo [2.2.2] octane derivatives useful as muscarinic receptor antagonists
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
WO2010018352A1 (en) 2008-08-12 2010-02-18 Argenta Discovery Limited Heterocyclic compounds used in the treatment of diseases where enhanced m3 receptor activation is implicated
GB0814728D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination
MX2011001577A (es) 2008-08-12 2011-05-02 Pulmagen Therapeutics Synergy Sal de 2-hidroxi-etansulfonato.
GB0814729D0 (en) 2008-08-12 2008-09-17 Argenta Discovery Ltd New combination

Also Published As

Publication number Publication date
CL2007003260A1 (es) 2008-05-23
MX2009004780A (es) 2009-05-21
JP4904402B2 (ja) 2012-03-28
US8207193B2 (en) 2012-06-26
RU2456286C2 (ru) 2012-07-20
NZ576679A (en) 2011-04-29
HRP20110178T1 (hr) 2011-04-30
JP2010509391A (ja) 2010-03-25
US20100029713A1 (en) 2010-02-04
PL2094694T3 (pl) 2011-05-31
TW200825084A (en) 2008-06-16
AR063804A1 (es) 2009-02-18
NO20092224L (no) 2009-06-22
KR20090078828A (ko) 2009-07-20
DK2094694T3 (da) 2011-04-04
AU2007321019A1 (en) 2008-05-22
RS51650B (en) 2011-10-31
CO6160312A2 (es) 2010-05-20
SA07280616B1 (ar) 2010-11-22
ECSP099338A (es) 2009-06-30
EP2094694B1 (de) 2011-01-26
WO2008059245A1 (en) 2008-05-22
HK1134091A1 (en) 2010-04-16
AU2007321019B2 (en) 2011-04-21
EP2094694A1 (de) 2009-09-02
IL198314A0 (en) 2010-02-17
CY1111351T1 (el) 2015-08-05
PT2094694E (pt) 2011-03-17
IL198314A (en) 2013-06-27
BRPI0718750A2 (pt) 2013-12-03
MY148392A (en) 2013-04-15
RU2009115829A (ru) 2010-12-20
DE602007012300D1 (de) 2011-03-10
CA2669326A1 (en) 2008-05-22
US20130005695A1 (en) 2013-01-03
EP2256117A1 (de) 2010-12-01
PE20081164A1 (es) 2008-10-31

Similar Documents

Publication Publication Date Title
ATE496916T1 (de) Chiniclidinderivate von (hetero)arylcycloheptancarbonsäuren als antagonisten am muskarinrezeptor
ATE421511T1 (de) Indol-3-carbonyl-spiro-piperidinderivate als antagonisten des v1a-rezeptors
ATE413874T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
ATE505467T1 (de) 2-aza-bicycloä3.1.0ühexanderivate als orexin- rezeptorantagonisten
NL1028624A1 (nl) Alfa-aryl- of -heteroarylmethyl-bèta-piperidinopropaan-zuurverbindingen als ORL1-receptorantagonisten.
ATE523195T1 (de) Neue thiophen-derivate als sphingosin-1-phosphat- 1-rezeptorantagonisten
DE602006015607D1 (de) Thiazol-4-carboxamid-derivate als mglur5-antagonisten
DE602005012249D1 (de) Chinolinoncarbonsäureamidverbindungen als 5-ht4-rezeptoragonisten
ATE555111T1 (de) Chinuclidinol-derivate als muscarinrezeptor- antagonisten
DE602007014374D1 (de) Ä4,5'ü-bipyrimidinyl-6,4'-diaminderivate als proteinkinase-hemmer
ATE518834T1 (de) 2,3,4,9-tetrahydro-1h-carbazol-derivative als crth2-rezeptorantagonisten
DK1863818T3 (da) Acetylenyl-pyrazolo-pyrimidinderivater som mglur2-antagonister
DE602005027307D1 (de) Arylanilinderivate als agonisten des beta2-adrenergen rezeptors
ATE481405T1 (de) Thiazolpyrazolopyrimidine als antagonisten des crf1-rezeptors
DK1973886T3 (da) Prokineticin-1-receptor-antagonister
ATE512966T1 (de) Pyrazolo-pyrimidin-derivate als mglur2- antagonisten
ATE394391T1 (de) Indolderivate als histaminrezeptorantagonisten
ATE509928T1 (de) 8-azabicycloä3.2.1üoktan-verbindungen als mu- opioid-rezeptorantagonisten
BRPI0910592A2 (pt) antagonistas de receptor 2 de somatostatina
NL2000241A1 (nl) Carboxamidederivaten als muscarine-receptorantagonisten.
DK2081951T3 (da) Progesteron-receptorantagonister
ATE487718T1 (de) Substituierte bizyklische pyrimidonderivate
ATE537149T1 (de) Sulfonyl-pyrazolinyl-1-carboxamidinderivate als 5-ht6-antagonisten
ATE454377T1 (de) 2-phenyl-6-aminocarbonylpyrimidinderivate und ihre verwendung als antagonisten am p2y12- rezeptor
ATE547407T1 (de) Alkylthiopyrimidine als crth2-antagonisten

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 2094694

Country of ref document: EP